Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Saved in:
| Title: | Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. |
|---|---|
| Authors: | Bosaeed M; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Balkhy HH; World Health Organization, Geneva, Switzerland., Almaziad S; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Aljami HA; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alhatmi H; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Alanazi H; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alahmadi M; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Jawhary A; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alenazi MW; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Almasoud A; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alanazi R; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Bittaye M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Aboagye J; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Albaalharith N; Department of Nursing, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia., Batawi S; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Folegatti P; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ramos Lopez F; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ewer K; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Almoaikel K; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Aljeraisy M; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alothman A; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Gilbert SC; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Khalaf Alharbi N; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. |
| Source: | The Lancet. Microbe [Lancet Microbe] 2022 Jan; Vol. 3 (1), pp. e11-e20. Date of Electronic Publication: 2021 Nov 03. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34751259 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bosaeed+M%22">Bosaeed M</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Balkhy+HH%22">Balkhy HH</searchLink>; World Health Organization, Geneva, Switzerland.<br /><searchLink fieldCode="AU" term="%22Almaziad+S%22">Almaziad S</searchLink>; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Aljami+HA%22">Aljami HA</searchLink>; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alhatmi+H%22">Alhatmi H</searchLink>; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alanazi+H%22">Alanazi H</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alahmadi+M%22">Alahmadi M</searchLink>; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Jawhary+A%22">Jawhary A</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alenazi+MW%22">Alenazi MW</searchLink>; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Almasoud+A%22">Almasoud A</searchLink>; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alanazi+R%22">Alanazi R</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Bittaye+M%22">Bittaye M</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Aboagye+J%22">Aboagye J</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Albaalharith+N%22">Albaalharith N</searchLink>; Department of Nursing, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Batawi+S%22">Batawi S</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Folegatti+P%22">Folegatti P</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Ramos+Lopez+F%22">Ramos Lopez F</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Ewer+K%22">Ewer K</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Almoaikel+K%22">Almoaikel K</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Aljeraisy+M%22">Aljeraisy M</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alothman+A%22">Alothman A</searchLink>; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Gilbert+SC%22">Gilbert SC</searchLink>; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Khalaf+Alharbi+N%22">Khalaf Alharbi N</searchLink>; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101769019%22">The Lancet. Microbe</searchLink> [Lancet Microbe] 2022 Jan; Vol. 3 (1), pp. e11-e20. <i>Date of Electronic Publication: </i>2021 Nov 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101769019 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-5247 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226665247%22">26665247 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Microbe |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34751259 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2666-5247(21)00193-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e11 Titles: – TitleFull: Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bosaeed M – PersonEntity: Name: NameFull: Balkhy HH – PersonEntity: Name: NameFull: Almaziad S – PersonEntity: Name: NameFull: Aljami HA – PersonEntity: Name: NameFull: Alhatmi H – PersonEntity: Name: NameFull: Alanazi H – PersonEntity: Name: NameFull: Alahmadi M – PersonEntity: Name: NameFull: Jawhary A – PersonEntity: Name: NameFull: Alenazi MW – PersonEntity: Name: NameFull: Almasoud A – PersonEntity: Name: NameFull: Alanazi R – PersonEntity: Name: NameFull: Bittaye M – PersonEntity: Name: NameFull: Aboagye J – PersonEntity: Name: NameFull: Albaalharith N – PersonEntity: Name: NameFull: Batawi S – PersonEntity: Name: NameFull: Folegatti P – PersonEntity: Name: NameFull: Ramos Lopez F – PersonEntity: Name: NameFull: Ewer K – PersonEntity: Name: NameFull: Almoaikel K – PersonEntity: Name: NameFull: Aljeraisy M – PersonEntity: Name: NameFull: Alothman A – PersonEntity: Name: NameFull: Gilbert SC – PersonEntity: Name: NameFull: Khalaf Alharbi N IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2022 Jan Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2666-5247 Numbering: – Type: volume Value: 3 – Type: issue Value: 1 Titles: – TitleFull: The Lancet. Microbe Type: main |
| ResultId | 1 |
